Company intelligence / Profile preview

Orphagen Pharmaceuticals

San Diego, California, USAorphagen.com ↗

Ownership: Private
Development stage: Other

Overview

Orphagen is developing novel small molecule therapies targeting unexplored nuclear receptors for cancer and autoimmune diseases. Their lead candidate, OR-449, is a first-in-class SF-1 antagonist for adrenocortical carcinoma.

Therapeutic areas: GastroenterologyOncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

OR-812

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Strategic partnerships for RORγ antagonists with mid-sized pharmaceutical companies

Beyond the preview

Go deeper on Orphagen Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orphagen Pharmaceuticals.

Explore the full profile